SHIP: Safety and Health Intervention Project

Sponsor
University of Michigan (Other)
Overall Status
Completed
CT.gov ID
NCT02152397
Collaborator
(none)
139
1
2
26
5.3

Study Details

Study Description

Brief Summary

Use of opioid medications for treatment of pain has increased greatly in the U.S., with the average quantity of prescribed opioids increasing 700% in a decade, from ~100 morphine milligram equivalents (MME) per person to ~700 MME per person from 1997 to 2007. There have been concurrent increases in opioid-related adverse outcomes, such as extramedical use, opioid use disorders, and overdose. As a result, there were more unintentional poisoning deaths than deaths due to motor vehicle crashes among adults in 2010 (32,723 vs. 32,640). Additionally, the number of Americans seeking treatment for opioid use disorders has increased; in SAMHSA's Treatment Episode Data Set, prescription opioids were the primary substance of abuse for 142,782 individuals in 2009, compared to 22,637 in 1999, a 530% increase.

The specific aims of this project are to: (1) Refine a motivational enhancement prevention intervention for prescription opioid overdose risk reduction and improved witnessed overdose response for at-risk patients in addictions treatment; (2) Conduct a pilot randomized controlled trial comparing the prescription opioid overdose prevention intervention to a supportive educational control condition for patients in addictions treatment in order to: (a) obtain information about the feasibility of randomized controlled procedures; and (b) determine the distribution and variability of the primary (overdose risk behaviors) and mediating/secondary (witnessed overdose response, self-efficacy to reduce overdose risk, knowledge of overdose risk factors and symptom recognition) outcomes; and (3) Determine the distribution and variability in changes in HIV risk behaviors (e.g., reductions in injection of prescription opioids) over follow-up.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Therapist-led brief intervention (TBI)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
139 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Developing a Prescription Opioid Overdose Prevention Intervention in Addictions Treatment
Actual Study Start Date :
Oct 1, 2014
Actual Primary Completion Date :
Dec 1, 2016
Actual Study Completion Date :
Dec 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Therapist-led brief intervention (TBI)

Participants will receive therapist-led, computer-assisted intervention sessions with a therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a "change plan" for each participant.

Behavioral: Therapist-led brief intervention (TBI)

No Intervention: Enhanced usual care

Participants will receive therapist-led, computer-assisted control sessions with a therapist.

Outcome Measures

Primary Outcome Measures

  1. Overdose risk behavior [Change over time (3- and 6-month post-baseline)]

    Overdose risk behavior will be measured for change over time using the Current Opioid Misuse Measure (COMM), Overdose Experience, Self and Witnessed (OESW), Overdose Risk Behavior (ORB) and Timeline Follow-Back (TLFB). The COMM is an 8 item scale assessing prescription pain medication use in the past months. It has a good test-retest reliability and an α=.93 in our prior studies. The OESW is an 11 item scale assessing experiences with overdoses in the past months (self and witnessed) which are related to drug use and psychosocial characteristics. The ORB is a 27 item scale assessing prescription opioid use, specific to the dose and type of opioid used, combination with other substances, route and if they use alone. The TLFB is a semi-structured interview assessing alcohol and drug use. This instrument has test-retest reliability >.86. All of these measures have been validated.

  2. HIV risk behavor [Change over time (3- and 6-months post-baseline)]

    HIV risk behavior will be measured for change over time using the HIV Risk Behavior Scale (HRBS), HIV testing (HT), Sexual Behaviors (SB) and HIV Risk Questionnaire - Timeline Follow-Back (HRQ-TLFB). The HRBS is a 6 item scale assessing individual HIV risk in regard to drug use. It is derived from an 11 item scale assessing both drug and sexual HIV risk behaviors, and has test-retest reliability >.85. The HT is a 4 item scale assessing testing history and knowledge of own HIV status. The SB is a 30 item scale assessing sexual risk behavior over the past months to assess for HIV risk. The HRQ-TLFB is a semi-structure interview measuring sex and drug HIV risk behavior. It has strong psychometric properties among those with substance use disorders (SUD).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients 18 and older in treatment at CPI

  • able to provide informed consent.

Exclusion Criteria:
  • acute suicidality

  • psychiatric condition that precludes participation in the intervention

  • inability to speak and understand English

  • inability to give informed, voluntary, written consent for any reason

Contacts and Locations

Locations

Site City State Country Postal Code
1 Community Programs, Inc. Waterford Michigan United States 48327

Sponsors and Collaborators

  • University of Michigan

Investigators

  • Principal Investigator: Amy Bohnert, PhD, University of Michigan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amy S.B. Bohnert, Assistant Professor, University of Michigan
ClinicalTrials.gov Identifier:
NCT02152397
Other Study ID Numbers:
  • 1R34DA035331-01A1
First Posted:
Jun 2, 2014
Last Update Posted:
Apr 17, 2017
Last Verified:
Apr 1, 2017
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 17, 2017